

GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

Date: 30.04.2021

To
The Manager
Listing Department
BSE Limited
Bombay Stock Exchange,
P. J. Towers, Dalal Street,
Mumbai-400001.

Ref: Scrip code 956084 and ISIN INE988W07019

Subject: Submission under Regulation 52(1), 52(4), 52 (7), 54 (2) and 56 (1)(d) of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015.


Dear Sir/Madam,

With reference to the subject matter, please find enclosed the following:

- i. The unaudited financial results of the Company for the half year ended 31st March, 2021 along with the Limited Review Report for that period issued by the Statutory Auditors under SEBI (LODR), 2015.
- ii. The disclosure of the items as required under Regulation 52(4) of SEBI (LODR), 2015 (Annexure 1).
- iii. A statement pursuant to Regulation 52(7) of SEBI (LODR), 2015.
- iv. A disclosure under Regulation 54(2) of SEBI (LODR), 2015.
- v. A Certificate under Regulation 56 (1)(d) of SEBI (LODR), 2015.

Please take the above information on your records.

For Genlink Pharma Solutions Private Limited



Itishree Garg
Company Secretary and Compliance Officer
Membership No. ACS46259

GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly Genlink Pharma Investments Private Limited)

CIN No : U74110MH2016PTC280765


Regd Off. Office No - 1701, 17th Floor, Kesar Solitaire, Plot No. 5, Sector 19, Sanpada Navi Mumbai, 400705, Maharashtra, India.

Standalone Unaudited Financial Results for the Half Year ended 31st March 2021

INR

Sr. No.	Particulars	Half Year Ended		Year to date ended	Previous Year Ended
		31-Mar-21	31-Mar-20	31-Mar-21	31-Mar-20
		Unaudited	Unaudited	Unaudited	Audited
1	Income from Operations				
(i)	Net Sales/Income from Operations (Net of excise duty)	1,980,000	1,980,000	3,960,000	3,960,000
(ii)	Other Income	-	-	-	-
	Total Income from Operations	1,980,000	1,980,000	3,960,000	3,960,000
2	Expenses				
(i)	Cost of Material Consumed	-	-	-	-
(ii)	Purchase of Stock in trade	-	-	-	-
(iii)	Change in Inventory of Finished Goods, Work In progress and Stock in trade	-	-	-	-
(iv)	Employee Benefits Expenses	-	-	-	-
(v)	Depreciation and Amortization Expenses	255,021	256,423	511,443	512,845
(vi)	Finance Cost	1,040,162	1,118,541	2,177,234	2,291,655
(vii)	Other Expenses	614,477	447,416	933,155	701,117
	Total Expenses	1,909,660	1,822,380	3,621,833	3,505,617
3	Profit/(Loss) from operation before tax	70,340	157,620	338,167	454,383
4	Tax Expenses	125,700	7,488	175,700	84,913
5	Profit/(Loss) from ordinary activities for the period	(55,360)	150,132	162,467	369,470
6	Other Comprehensive Income				
(i)	Items that will not be reclassified to profit or loss	-	-	-	-
(ii)	Items that will be reclassified to profit or loss	-	-	-	-
	Total Comprehensive Income/(Loss) for the period	(55,360)	150,132	162,467	369,470
7	Paid up Equity Share Capital of 10/- each	100,000	100,000	100,000	100,000
8	Earning per Share(not annualised)				
	Basic	(5.54)	15.01	16.25	36.95
	Diluted	(5.54)	15.01	16.25	36.95

For Genlink Pharma Solutions Private Limited




Susheel Koul
 Managing Director
 DIN: 00925887

Anand Shah
 Director
 DIN: 00597145


Date: 28th April, 2021

Place: Navi Mumbai

GENLINK PHARMA SOLUTIONS PRIVATE LIMITED
(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)
STANDALONE BALANCE SHEET AS AT 31st March, 2021

Particulars	Note No.	(Amount in INR)	
		As at 31 March 2021 (Unaudited)	As at 31 March 2020 (Audited)
I. ASSETS			
1 Non-current assets			
(a) Property, Plant & Equipment	2	29,409,414	29,920,857
(b) Non-current investments	3	248,995,479	248,995,479
2 Current assets			
(a) Trade receivables	4	26,254	653,950
(b) Cash and cash equivalents	5	6,014,593	2,563
(d) Other current assets	6	501,931	324,500
TOTAL		284,947,670	279,897,349
II. EQUITY AND LIABILITIES			
1 Equity			
(a) Share capital	7	100,000	100,000
(b) Other Equity	8	2,659,790	2,497,322
2 Non-current liabilities			
(a) Financial Liabilities			
(i) Long-term borrowings	9	27,357,066	271,889,120
3 Current liabilities			
(a) Financial Liabilities			
(i) Borrowings	10	250,000,000	-
(ii) Other financial liabilities	11	4,613,315	5,235,907
(b) Current tax liabilities & Provisions	12	217,500	175,000
TOTAL		284,947,671	279,897,349

For Genlink Pharma Solutions Private limited



Anand Shah
Director
DIN: - 00597145
Navi Mumbai
Date : 28-Apr-2021



Susheel Koul
Managing Director
DIN: - 00925887
Navi Mumbai
Date : 28-Apr-2021

GENLINK PHARMA SOLUTIONS PRIVATE LIMITED
(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)
STANDALONE STATEMENT OF PROFIT AND LOSS FOR THE HALF YEAR ENDING 31 MARCH 2021

(Amount in INR)

Particulars	Refer Note No	For the year ended 31 March 2021 Unaudited	For Half year ended 31 March 2021 Unaudited	For the year ended 31 March 2020 (Audited)
I REVENUE				
Revenue from operations	12	3,960,000	1,980,000	3,960,000
Total Revenue		3,960,000	1,980,000	3,960,000
II EXPENSES				
Finance costs	13	2,177,234	1,040,162	2,291,655
Depreciation and amortisation expenses	14	511,443	255,021	512,845
Other expenses	15	933,155	614,477	701,117
Total expenses		3,621,833	1,909,660	3,505,617
III Profit/(Loss) before tax (I-II)		338,167	70,340	454,384
IV Tax expense				
Current tax		175,700	125,700	84,000
(Excess)/Short Provision for Tax		-	-	913
V Profit/(Loss) after tax (III-IV)		162,467	(55,360)	369,471
VI Earnings Per Share				
-Basic & Diluted		16.25	(5.54)	36.95

For Genlink Pharma Solutions Private limited

Anand Shah
Director
DIN: - 00597145
Navi Mumbai
Date : 28-Apr-2021

Susheel Koul
Managing Director
DIN: - 00925887
Navi Mumbai
Date : 28-Apr-2021



Independent Auditor's Limited Review Report on the Unaudited Financial Results of the Company for the half year ended 31st March 2021 pursuant to the Regulation 52 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended

**Review Report to
The Board of Directors
M/S GENLINK PHARMA SOLUTIONS PRIVATE LIMITED,
(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)
Mumbai**

Re: Limited Review Report of the Unaudited Financial Results for the half year from 1st October, 2020 to 31st March, 2021.


Introduction

We have reviewed the accompanying statement of Unaudited Financial Results of **M/s. GENLINK PHARMA SOLUTIONS PRIVATE LIMITED, (Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)**, ("the Company"), for the half year from 1st October, 2020 to 31st March, 2021 ("the Statement"), attached herewith being submitted by the Company pursuant to the requirement of Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('the regulation') as amended (the "Listing Regulation"). This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, ('Ind AS 34') "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, read with the Circular is the responsibility of the Company, management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement based on our review.

Scope of Review

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



Shankarlal Jain & Associates LLP

Chartered Accountants



12, Engineer Building, 265 Princess Street, Mumbai - 400 002. India E-mail : info@sljainindia.com

Tel : +91 22 2203 6623, 2206 5739 Fax : +91 22 2208 6269 Website : www.sljainindia.com

Conclusion

Based on our review, conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**FOR SHANKARLAL JAIN & ASSOCIATES LLP
CHARTERED ACCOUNTANTS
FIRM REG NO: - 109901W/W100082**



**SATISH JAIN
PARTNER
MEMBERSHIP NO.: 048874
UDIN: 21048874AAAAAX4634**

**Place : Mumbai
Date : 28-04-2021**

GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

DISCLOSURE UNDER REGULATION 52(4) OF SEBI (LODR), 2015

With reference to Regulation 52 (4) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find disclosure as under for the half year ended 31st March, 2021

- 1. Credit rating** - The Company's NCDs have been rated as "ACUITE B-" by Acuite Ratings & Research Limited (formerly known as SMERA Ratings Limited). There has been change in the credit rating of the Company from "ACUITE B" to "ACUITE B-".
- 2. Asset cover available** - The asset cover ratio works out to more than one time on the basis of valuation of the equity shares offered as security for the NCDs.
- 3. Debt-equity ratio - 100.92 times**
- 4. Previous due date for the payment of interest** - The Company has issued "Zero Coupon" secured redeemable non-convertible debentures. Hence, no interest is required to be paid.
- 5. Repayment of principal of non-convertible debt securities** - The secured redeemable non-convertible debentures are redeemable in full on September 27, 2021.
- 6. Next due date for the payment of interest** - The Company has issued "Zero Coupon" secured redeemable non-convertible debentures. Hence no due date is applicable.
- 7. Debt service coverage ratio - 0.01 times**
- 8. Interest service coverage ratio - 1.39 times**
- 9. Outstanding redeemable preference shares (quantity and value)** - The Company does not have any outstanding redeemable preference shares.
- 10. Capital redemption reserve/debenture redemption reserve - Rs 0/-**
- 11. Net worth** - The net worth of the Company is Rs. 27,59,790/-
- 12. Net profit after tax**
Net profit after tax of the Company is Rs. (55,360)/-

GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

13. Earnings per share

Earnings per share of the Company is Rs. -5.54/-

For Genlink Pharma Solutions Private Limited



Itishree Garg

Company Secretary and Compliance Officer

Membership No. ACS46259

GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

DISCLOSURE PURSUANT TO REGULATION 52 (7) OF THE SEBI (LODR), 2015

We hereby state that for the half year ended 31st March, 2021 there is no material deviation in the use of proceeds of Secured Redeemable Non-Convertible Debentures from the objects stated in the offer document.

For Genlink Pharma Solutions Private Limited



Itishree Garg
Company Secretary and Compliance Officer
Membership No. ACS46259

GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

DISCLOSURE UNDER REGULATION 54 OF SEBI (LODR), 2015

We hereby state that the Company maintains as on half year ended 31st March, 2021 hundred percent asset cover sufficient to discharge the principal amount at all times for the non-convertible debt securities issued.

The details of extent and nature of security created and maintained with respect to its listed secured non-convertible redeemable debt securities are as follows:

1. 563,497 Equity shares of Enaltec Labs Pvt. Ltd. held by Genlink Pharma Solutions Private Limited.
2. 5,923 Equity shares of Enaltec Labs Pvt. Ltd. held by Mr. Anand Shah.
3. 5,923 Equity shares of Enaltec Labs Pvt. Ltd. held by Mr. Susheel Koul.

For Genlink Pharma Solutions Private Limited



Itishree Garg

Company Secretary and Compliance Officer

Membership No. ACS46259

Office: 1701, 17th Floor, Kesar Solitaire, Plot No. 5, Sector 19, Sanpada, Navi Mumbai - 400 705, India

Ph: +91 22 6750 7000 Fax +91 22 6750 7070 Email genlinkinfo@gmail.com www.genlinkpharma.com

CIN: U74110 MH 2016 PTC 280765



Certificate for asset cover by debenture trustee in respect of listed debt securities of the listed entity

To,
Stock Exchange(s)

Based on examination of books of accounts and other relevant records/documents of **GENLINK PHARMA SOLUTIONS PRIVATE LIMITED**, (CIN U74110MH2016PTC280765) having its registered office at 1701, 17th Floor, Kesar Solitaire, Plot No 5, Sector 19, Sanpada, Navi Mumbai - 400705, we hereby certify that:

- a) The listed entity has vide its Board Resolution and information memorandum/ offer document and under various Debenture Trust Deeds, has issued the following listed debt securities:

ISIN	Private Placement/ Public Issue	Secured/ Unsecured	Sanctioned Amount
INE988W07019	Private Placement	Secured Non-Convertible Debentures	Rs. 25.00 Crore

- b) Asset Cover for listed debt securities:

- i. The financial information as on **31st March, 2021** has been extracted from the books of accounts for the year ended 31st March, 2021 and other relevant records of the listed entity;
- ii. The assets of the listed entity provide coverage of **1.10 times** of the interest and principal amount, which is in accordance with the terms of issue/ debenture trust deed (calculation as per statement of asset cover ratio for the Secured debt securities - table - I)
- iii. The total assets of the listed entity provide coverage of **Not Applicable** times of the principal, which is in accordance with the terms of issue (calculation as per statement of asset coverage ratio available for the unsecured debt securities - table - II) (as per requirement of Regulation 54 read with Regulation 56(1)(d) of LODR Regulations).





Table - I:

Sr. No.	Particulars		Amount in Rs. Crore
i.	Total assets available for secured Debt Securities' - (secured by either pari passu or exclusive charge on assets) (mention the share of Debt Securities' charge holders)	A	27.61
	• Property Plant & Equipment (Fixed assets) - movable/immovable property, etc.		Nil
	• Loans /advances given (net of provisions, NPAs and sell down portfolio), Debt Securities, other credit extended, etc.		Nil
	• Receivables including interest accrued on Term loan/ Debt Securities, etc.		Nil
	• Investment(s)		27.61
	• Cash and cash equivalents and other current/ Non-current assets.		Nil
ii.	Total borrowing through issue of secured Debt Securities (secured by either pari passu or exclusive charge on assets)	B	25.00
	• Debt Securities (Provide details as per table below)		25.00
	• IND - AS adjustment for effective Interest rate on secured Debt Securities		Nil
	• Interest accrued/payable on secured Debt Securities		Nil
iii.	Asset Coverage Ratio (100% or higher as per the terms of offer document/information memorandum/ debenture trust deed)	A/B	1.10

Sr. No.	ISIN	Facility	Type of charge	Sanctioned Amount (Rs. Crores)	Outstanding Amount As On 31/12/20 (Rs. Crores)	Cover Required (Rs. Crores)	Assets Required (Rs. Crores)
1	INE988W07019	Private Placement of Secured Non-Convertible Debentures	Exclusive	25.00	25.00	25.00	25.00

Table - II

Sr.No	Particulars		Amount
i.	Net assets of the listed entity available for unsecured lenders (Property Plant & Equipment (excluding intangible assets and prepaid expenses) + Investments + Cash & Bank Balances + Other current/ Non-current assets excluding deferred tax assets (-) Total assets available for secured lenders/creditors on pari passu/exclusive charge basis under the above heads (-) unsecured current/ non-current liabilities (-) interest accrued/ payable on unsecured borrowings)	A	NA
ii.	Total Borrowings (unsecured)	B	NA
	Term loan		NA
	Non-convertible Debt Securities		NA
	CC/ OD Limits		NA
	Other Borrowings		NA
	IND - AS adjustment for effective Interest rate on unsecured borrowings		NA
iii.	Assets Coverage Ratio (100% or higher as per the terms of Offer Document/Information Memorandum/ Debenture Trust Deed)	(A/B)	NA





c) Compliance of all the covenants/terms of the issue in respect of listed debt securities of the listed entity

We have examined the compliances made by the listed entity in respect of the covenants/terms of the issue of the listed debt securities (NCD's) and certify that such covenants/terms of the issue have been complied by the listed entity.



Place: Mumbai
Date: 28-04-2021

FOR SHANKARLAL JAIN & ASSOCIATES LLP,
CHARTERED ACCOUNTANTS
FIRM REG NO: - 109901W/W100082

SATISH JAIN
Partner
Membership No.: 048874
UDIN : 21048874AAAAAZ4514